This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Trial Evaluating Use of Arista in Total Thyroidectomy

Sponsored by University of California, San Francisco

About this trial

Last updated 6 years ago

Study ID

Arista for Thyroids

Status

Withdrawn

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 8 years ago

What is this trial about?

This is a single-blinded randomized controlled trial to evaluate the effectiveness of Arista hemostatic matrix powder (Arista® AH, C. R. Bard, Inc. Davol, Warwick, RI) in reducing drainage output after total thyroidectomy with and without lateral neck dissections. Increased drainage in total thyroidectomy and neck dissection wound beds can lead to seroma formation with possible secondary infection, delayed hospital discharge, and additional home care needs for drain care. Arista is an inert plant based absorbable surgical hemostatic powder that can be easily applied to broad surgical fields to reduce bleeding and seroma rates. Therefore, its application to thyroidectomy and neck dissection wound beds may bear significant potential benefit.

What are the participation requirements?

Yes

Inclusion Criteria

- Patients undergoing Total Thyroidectomy with or without lateral neck dissection

- Patient must be 18 years of age or older.

- The patient must have capacity to be able to sign a study-specific informed consent prior to study

No

Exclusion Criteria

- Pregnancy (for female patients).

- Patients who will require anticoagulant medications other than routine DVT prophylaxis within 8 days postoperatively.

- Presence of clotting or bleeding disorder.